Company: ZVRA
Filing Date: 2025-03-31
Form Type: DEFA14A
Source: 0001193125-25-068941
Chunk: 1

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: DEFA14A
Chunk 1
---
 of whom are independent, seven of whom have joined the Board since 2023, and all of whom have been actively engaged in overseeing
Zevra’s transformation into a more focused organization with full commercial capabilities and a strong balance sheet that is creating value for patients and stockholders. The two incumbent directors nominated for
re-election collectively bring over 70 years of life sciences industry experience, deepening the Board’s collective expertise in drug development, commercialization, and financial strategy. Dr. Dixon
is a member of the Company’s Audit Committee, and Ms. Favorito has served as Board Chair since 2023 and as the Audit Committee Chair since 2021.

In its preliminary proxy statement, the Company also disclosed that a stockholder, Daniel J. Mangless, is proposing the election of two candidates to the
Board of Directors, Travis C. Mickle, Ph.D. and Arthur C. Regan. Given the Company’s strong momentum with respect to its strategic plan, the Zevra Board believes that a proxy contest is not in the best interests of the Company or its
stockholders. The addition of Mr. Mangless’ nominees, which include Dr. Mickle, who cannot be considered independent due to his former roles as CEO and President of the Company until his resignation in 2023 and his ongoing consulting
arrangement with the Company until 2024, could be highly disruptive to Board dynamics and impede management’s continued execution of its strategic plan. As such, Zevra’s Board recommends that stockholders reject these efforts by
Mr. Mangless, which are not in the best interests of all stockholders.

The Company today issued the following statement:

“Zevra has made tremendous progress over the last two years, with our Board and management team working closely to transform the Company
into a more efficient, more focused organization that is better positioned to create value for our patients and stockholders. We continue to deliver across the four pillars of the five-year strategic plan we detailed in late 2024, which are
commercial excellence, pipeline and innovation, talent and culture, and corporate foundation. We have a clear path forward to generate value for our stakeholders as we continue our evolution into a leading rare disease company.

Since our 2023 annual meeting of stockholders, we launched our first two products, conducted a comprehensive review of our pipeline and
portfolio to ensure that we are invested in the highest return opportunities, significantly strengthened and refreshed our Board, strengthened our leadership team, and reinforced our strong financial foundation